Developed by Sarepta Therapeutics, Elevidys is a one-time, intravenous treatment that uses adeno-associated virus (AAV) ...

Pediatric neurologist Omer Abdul Hamid is one of the few doctors in the US who administer gene therapy for Duchenne muscular ...

New data demonstrated the benefits of Elevidys, a gene therapy for multiple Duchenne muscular dystrophy, in different age ...

Delandistrogene moxeparvovec (Elevidys; Sarepta Therapeutics) appeared to protect muscle from progressive damage in patients ...

Italfarmaco's oral HDAC inhibitor Duvyzat has been recommended for approval in the EU as a treatment for Duchenne muscular dystrophy ... showed slower disease progression over 18 months of ...

Muscle weakness has the biggest impact on patients’ ability to walk, but other factors matter too, researchers found.

Sarepta Therapeutics (NASDAQ:SRPT) and its partner Roche (OTCQX:RHHBY) received a 'go ahead' from the regulatory body in U.K.

However, in limb-girdle or facioscapulohumeral dystrophy little or no progression of weakness ... that the underlying molecular defect in Duchenne muscular dystrophy was affected by physical ...

Through years of rigorous research, Duvyzat has consistently demonstrated a favourable risk-benefit profile and the potential to significantly delay disease progression across a broad range of ...